Michiel S. van der Heijden

nobleid.org/michielsvanderheijden

Bladder and Urothelial Cancer Treatments Cancer Immunotherapy and Biomarkers Urinary and Genital Oncology Studies Urinary Bladder and Prostate Research Cancer Genomics and Diagnostics

Created: Nov 10, 2026

•Updated: Nov 10, 2026

Public URLs (2)

https://nobleid.org/NI8P85W49R98S48 https://nobleid.org/michielsvanderheijden

Affiliations

The Netherlands Cancer Institute

2010 - Present

Cited by

Measure	All
Citations	27,388
h-index	56
i10-index	129

As of Oct 14, 2026 · 355 works

Works (300)

285 on NobleID · 15 being added

Title	Cited by	Year
TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells Nature	5,349	2018
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial The Lancet	3,665	2016
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial The Lancet	2,198	2016
Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial The Lancet	1,408	2017
Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer New England Journal of Medicine	1,103	2024

Sign in to see the full profile

Creating an account is free.

Create an account

For data access, contact info@nobleid.org.